Replies to post #690764 on NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

Opdivo and Yervoy were approved for adding two months to mOS.

[kabunushi]

Thanks, Gary! I'm no expert on the RAs but it certainly would seem super near-sighted to completely ignore the fantastic clinical results from dc-vax led combination therapies, even though the numbers are small on those trials and the trials are not run by NWBO hence maybe not even formally mentioned in their current application (I would not know if that is true or not). It just looks like there is in any case incredible promise for this hyper-deadly disease from heading in that direction with all due haste. Even if the RAs are hidebound pure formalists, how can they not understand and consider what is at stake here? There are a lot of patient lives at stake. Especially with the safety profile for dc-vax, it just seems like it's a no-brainer and by far the compassionate thing to do to let this therapy loose on the world asap.

[biosectinvestor]

The 13% look like they are effectively cured. That's not the standard for approval of new cancer drugs. I f it were, there would be no other drugs approved in this space or virtually any other cancer space and drugs like Keytruda, would not even be on the market for most cancers.

Don't let people trick you into arguing on false framing of the question.

There is a survival benefit across the entire population treated. There are especially good results for many patients who typically do poorly. They have a survival benefit out of this world for the 13%, which is completely beyond what would normally be expected for an approved drug.

And lastly, they have indicia that combinations, as with poly-iclc and potentially adding also Keytruda ultimately, there will be a much larger expansion of patients living longer and without recurrence to a level typically unheard of for brain cancer and even generally for many other cancers.

That anyone has people freaking out and fearing with this kind of data, speaks to the power of misinformation and disinformation, repeatedly posted, to create false impressions.

[The Danish Dude]

There were many reasons why Al Musella was threatened to take down the webinar with Linda Liau december 5th. 2022, remove the Q&A and put it up again.

That Q&A would've destroyed the most frequently used fud narratives since then, which we've been wasting thousands of posts and hours going in circles around.

For one of the most hardcore fudders it was his Waterloo, leading to a puzzle of a retreat, when littering the Nature article in the comments section with ...

...as there can be wide confusion in this namespace I think it would be proper to update (or note) the formal name of the ATL-DC agent used

Poor thing. Yes, it definitely lead to confusion in this socalled namespace of his, the fud habitat. How would they now be able to continue the two years of having successfully pleaded ignorance on this subject, in which no other namespaces have enjoyed said confusion?

... leading to next in line of controversial topics Linda Liau talked about, combo trial with poly-iclc and a very interesting comment from her.

"When approved poly-iclc can be added off label".

I bet there is some confusion in a certain safespace regarding that.

Here's also an interesting comment from Peter Davis on that.

#dcvax $nwbo #gbm

Excellent post by Chiugray

TiltMyBrain, DCVax is about to give a knockout 1-2 punch against brain tumors and will mark a historic moment to the joy of cancer patients and oncologists.

1. Regulatory approvals (first UK, then globally) DCVax-L for stage 4… pic.twitter.com/82pcsTkwB3

— Peter Davis (@peter_brit) May 9, 2024

Will we ever see DCVax-L be used alone, when approved?

What would be the point?

Are Linda Liau correct?

If yes, it would be a ball buster, a big one ... and no wonder some threatened Al over that one.

[iclight]

You’ve been corrected 100 times on your made up 5% number. There is no control arm with the same inclusion/exclusion criteria as the treatment arm that the company will divulge. They won’t release that data.

The 5% is from ALL GBM patients including those with biopsy only and those with a terrible prognosis at diagnosis. They were excluded from the trial. Why can’t just admit you are wrong?